JP2022515373A5 - - Google Patents
Info
- Publication number
- JP2022515373A5 JP2022515373A5 JP2021534632A JP2021534632A JP2022515373A5 JP 2022515373 A5 JP2022515373 A5 JP 2022515373A5 JP 2021534632 A JP2021534632 A JP 2021534632A JP 2021534632 A JP2021534632 A JP 2021534632A JP 2022515373 A5 JP2022515373 A5 JP 2022515373A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- composition according
- disease
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4 | 2018-12-18 | ||
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515373A JP2022515373A (ja) | 2022-02-18 |
| JP2022515373A5 true JP2022515373A5 (cg-RX-API-DMAC7.html) | 2022-12-26 |
| JP7515480B2 JP7515480B2 (ja) | 2024-07-12 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534632A Active JP7515480B2 (ja) | 2018-12-18 | 2019-12-18 | 認知障害の治療に使用するための3β-(ベンジルオキシ)-17α-メチル-プレグン-5-エン-20-オン |
Country Status (26)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007382A (es) | 2018-12-18 | 2021-07-15 | Merck Sharp & Dohme Llc | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih. |
| WO2024085245A1 (ja) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004234125A1 (en) | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
| ATE496894T1 (de) | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| CN101790521A (zh) | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| CN106983754A (zh) | 2011-05-20 | 2017-07-28 | 国家医疗保健研究所 | Cb1受体拮抗剂 |
| RU2667065C2 (ru) * | 2012-11-28 | 2018-09-14 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Производные прегненолона |
| LT2976074T (lt) * | 2013-03-19 | 2020-03-25 | Universitat Pompeu-Fabra | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis |
| IL276697B2 (en) | 2018-02-20 | 2024-08-01 | Aelis Farma | 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 US US17/414,826 patent/US12583884B2/en active Active
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515293A5 (cg-RX-API-DMAC7.html) | ||
| JP2020504156A5 (cg-RX-API-DMAC7.html) | ||
| JP2017531020A5 (cg-RX-API-DMAC7.html) | ||
| JP2022549335A5 (cg-RX-API-DMAC7.html) | ||
| ES2634204T3 (es) | Composición farmacéutica que comprende derivados de piridona | |
| JP2022539152A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020138491A5 (cg-RX-API-DMAC7.html) | ||
| JP2015525766A (ja) | 神経変性障害を治療するためのテトラサイクリン化合物 | |
| CN103732594A (zh) | 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐 | |
| JP2022519744A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532968A5 (cg-RX-API-DMAC7.html) | ||
| JP2011516588A5 (cg-RX-API-DMAC7.html) | ||
| JP2005508381A5 (cg-RX-API-DMAC7.html) | ||
| RU2021117520A (ru) | 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| JPWO2021153665A5 (cg-RX-API-DMAC7.html) | ||
| Lim et al. | A case of Stevens-Johnson syndrome probably induced by herbal medicine | |
| JP2025506201A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0407140A (pt) | Droga terapêutica para vìrus | |
| PT1656458E (pt) | Gene humano de susceptibilidade ao autismo e suas utilizações | |
| Lanzenberger et al. | Sex differences in neurology and psychiatry | |
| RU2222327C2 (ru) | Способ получения лекарственного препарата | |
| CN106946701B (zh) | 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用 | |
| FI3909568T3 (fi) | Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin | |
| Younger | Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders | |
| JP2024511945A5 (cg-RX-API-DMAC7.html) |